CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes
- PMID: 25666713
- PMCID: PMC4322368
- DOI: 10.1038/srep08366
CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes
Erratum in
-
Erratum: CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes.Sci Rep. 2015 Jul 15;5:9731. doi: 10.1038/srep09731. Sci Rep. 2015. PMID: 26177189 Free PMC article. No abstract available.
Abstract
The era of genomics has demanded the development of more efficient and timesaving approaches to validate gene function in disease. Here, we utilized the CRISPR-Cas9 system to generate Kcnj13 mutant mice by zygote injection to verify the pathogenic role of human KCNJ13, mutations of which are thought to cause Leber congenital amaurosis (LCA), an early-onset form of blindness. We found that complete loss of Kcnj13 is likely postnatal lethal. Among surviving F0-generation mice examined, 80% show mosaic KCNJ13 expression in the retinal pigment epithelium (RPE). Mosaic expression correlates with decreased response to light and photoreceptor degeneration, indicating that Kcnj13 mutant mice mimic human KCNJ13-related LCA disease. Importantly, mosaic animals enable us to directly compare Kcnj13 mutant and wild-type RPE cells in the same eye. We found that RPE cells lacking KCNJ13 protein still survive but overlying photoreceptors exhibit cell degeneration. At the same time, wild-type RPE cells can rescue neighboring photoreceptor cells that overlie mutant RPE cells. These results suggest that KCNJ13 expression is required for RPE cells to maintain photoreceptor survival. Moreover, we show that CRISPR-Cas9 engineered mosaicism can be used to rapidly test candidate gene function in vivo.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4322368/bin/srep08366-f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4322368/bin/srep08366-f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4322368/bin/srep08366-f3.gif)
Similar articles
-
Conditional loss of Kcnj13 in the retinal pigment epithelium causes photoreceptor degeneration.Exp Eye Res. 2018 Nov;176:219-226. doi: 10.1016/j.exer.2018.07.014. Epub 2018 Jul 25. Exp Eye Res. 2018. PMID: 30009826 Free PMC article.
-
Gene Augmentation and Readthrough Rescue Channelopathy in an iPSC-RPE Model of Congenital Blindness.Am J Hum Genet. 2019 Feb 7;104(2):310-318. doi: 10.1016/j.ajhg.2018.12.019. Epub 2019 Jan 24. Am J Hum Genet. 2019. PMID: 30686507 Free PMC article.
-
KCNJ13 Gene Deletion Impairs Cell Alignment and Phagocytosis in Retinal Pigment Epithelium Derived from Human-Induced Pluripotent Stem Cells.Invest Ophthalmol Vis Sci. 2020 May 11;61(5):38. doi: 10.1167/iovs.61.5.38. Invest Ophthalmol Vis Sci. 2020. PMID: 32437550 Free PMC article.
-
Focus on Kir7.1: physiology and channelopathy.Channels (Austin). 2014;8(6):488-95. doi: 10.4161/19336950.2014.959809. Channels (Austin). 2014. PMID: 25558901 Free PMC article. Review.
-
Stem cell based therapies for age-related macular degeneration: The promises and the challenges.Prog Retin Eye Res. 2015 Sep;48:1-39. doi: 10.1016/j.preteyeres.2015.06.004. Epub 2015 Jun 23. Prog Retin Eye Res. 2015. PMID: 26113213 Review.
Cited by
-
Correspondence of Yolk Sac and Embryonic Genotypes in F0 Mouse CRISPants.Med Res Arch. 2023 Jun 30;11(6):10.18103/mra.v11i6.3989. doi: 10.18103/mra.v11i6.3989. Epub 2023 Jun 26. Med Res Arch. 2023. PMID: 37885852 Free PMC article.
-
Therapeutic applications of CRISPR/Cas9 gene editing technology for the treatment of ocular diseases.FEBS J. 2023 Nov;290(22):5248-5269. doi: 10.1111/febs.16771. Epub 2023 Mar 27. FEBS J. 2023. PMID: 36877952 Review.
-
CRISPR-Cas9 Technology for the Creation of Biological Avatars Capable of Modeling and Treating Pathologies: From Discovery to the Latest Improvements.Cells. 2022 Nov 15;11(22):3615. doi: 10.3390/cells11223615. Cells. 2022. PMID: 36429042 Free PMC article. Review.
-
The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.Eye (Lond). 2023 Mar;37(4):607-617. doi: 10.1038/s41433-022-02169-1. Epub 2022 Aug 1. Eye (Lond). 2023. PMID: 35915232 Free PMC article. Review.
-
Current landscape of gene-editing technology in biomedicine: Applications, advantages, challenges, and perspectives.MedComm (2020). 2022 Jul 14;3(3):e155. doi: 10.1002/mco2.155. eCollection 2022 Sep. MedComm (2020). 2022. PMID: 35845351 Free PMC article. Review.
References
-
- Cho S. W., Kim S., Kim J. M. & Kim J. S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31, 230–2 (2013). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials